QIANHAI HEALTH (00911) announced its interim results for 2025, reporting revenue of approximately HK$341 million, representing an increase of 11.04% year-on-year. Net profit reached HK$4.774 million, declining 69.3% compared to the same period last year. Earnings per share stood at 2.82 HK cents.

Despite the revenue growth, gross profit for the interim period dropped significantly from approximately HK$42.9 million in the previous period to approximately HK$14.2 million. The decline in gross profit was primarily attributed to intensified market competition, which forced the group to sell electronic components products at lower gross margins.